Anti-histone Antibody-Cytokine Fusion Protein, dI-IgG-ala (NHS76)-IL2 (D20T) (CAT#: ACFP-SH115)

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-histone dI-IgG-ala to IL2 (D20T). It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the histone as well as the biological activity of IL2 (D20T). In NHS76-IL2, a mutation that eliminates a potential T-cell epitope in the variable region of the light chain was introduced. IL-2 derivative carrying a mutation at position 20 (D20T) was used, which exhibits a lower toxicity due to reduced activation of the intermediate-affinity IL-2 receptor. This immunocytokine was designed for treating necrotic tumor.